News | August 15, 2024
Evonik expands its formulation capabilities for lipid nanoparticles
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Valbenazine Capsules had annual sales of US $1,993.6 mn in the United States (IQVIA MAT June 2024)
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
He advocated for a "PPP + PPP" collaboration, urging the public and private sectors within India to partner with their counterparts in other countries
Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries
Subscribe To Our Newsletter & Stay Updated
